Daphne Lainson
Partner, Ottawa
Barrister and Solicitor,
Patent and Trademark Agent


Phone: 613.232.2486
Fax: 613.232.8440
Download V-Card
Ontario Bar 2001
  • Queen's University B.Sc. Hons. (Chemistry) 1994
  • Queen's University M.Sc. (Chemistry) 1996; thesis titled A computational study of lithium cation and sodium cation interaction with sulfuryl and phosphoryl species
  • University of Windsor LL.B. 1999
  • Registered Trademark Agent 2001
  • Registered Patent Agent 2002
  • Registered to practise before the United States Patent and Trademark Office

Daphne Lainson specializes in securing patent protection for chemical, pharmaceutical and biotechnology related inventions. She is a lawyer, a qualified patent and trademark agent, and holds an advanced degree in chemistry. She has been assisting clients with securing patent protection for their innovations for over a decade.

Daphne champions and safeguards the intellectual property rights of her clients, protecting their inventions in new drugs, biologics, medical devices, consumer products, agrochemicals, specialty chemicals, industrial chemical processes, oil, gas and petrochemicals.

She also provides advice to clients on pharmaceutical regulatory law. This includes providing strategic advice during patent prosecution and following patent grant for both pharmaceuticals and biologics. She is called upon to advise innovative pharmaceutical and biopharmaceutical companies in matters relating to data protection, the Patented Medicines (Notice of Compliance) Regulations and the Patented Medicine Prices Review Board.

Daphne is sought after to provide advice and guidance to many of the top global innovators.

She is actively involved in the American Intellectual Property Law Association (AIPLA). She is an AIPLA Fellow, and Vice-Chair of the Food and Drug Law Committee.  She is also past chair of the AIPLA IP Practice in Japan Committee, of the AIPLA Mentoring Committee and of the AIPLA Women in Intellectual Property Law Committee.

She plays a leading role in client relations management within the firm, particularly in key industrial markets, such as the U.S., Japan and Germany.

Rankings and recognition

  • Recognized as a World IP Review Leader in 2016 & 2017
  • Recognized annually in The Best Lawyers in Canada under Biotechnology Law since 2014 and Intellectual Property Law since 2015
  • Recognized annually in The Canadian Legal LEXPERT® Directory under Intellectual Property and Biotechnology since 2013
  • Recognized in the 2016 edition of Who's Who Legal: Patents
  • Recognized annually as an 'IP Star' since the inaugural edition in 2014 of Managing Intellectual Property’s IP Stars Handbook: Patents
  • The only Canadian to be nominated by Euromoney LMG Americas Women in Business Law Awards as a Rising Star in 2013
  • Named by Lexpert as one of Canada's 2012 Rising Stars — Leading Lawyers Under 40
  • Named Ottawa Businesswoman of the Year 2011 in the professional category by the Women's Business Network of Ottawa
Chemical & Industrial Biotechnology
Life Sciences
IP Management & Strategic Counselling
Life Sciences — Regulatory & Compliance
Agricultural Sciences


  • Fellow, Intellectual Property Institute of Canada
  • Member, American Intellectual Property Law Association; Vice-Chair of the Food and Drug Law Committee; Past co-chair of the Japan Practice Committee; past Chair of the Mentoring Committee; and past Chair of the Women in Intellectual Property Law Committee
  • Member, Chemical Institute of Canada, Canadian Society for Chemistry
  • Member, The Women's Business Network of Ottawa
  • Member, Canadian Bar Association; member of the Patent Committee

Speaking engagements

  • “Patent Listing and Data Protection: A Primer for Regulatory Affairs Professionals,” (speaker), CAPRA Dinner Meeting, Dorval, QC, January 2016
  • “Biosimilars are Off and Running: A Litigation and Regulatory Update” (moderator), AIPLA Annual Meeting, 2015
  • "Subsequent Entry Biologics (SEBs) – Canada," AIPLA Mid-Winter meeting , Las Vegas, NV, January 2012; AIPLA webinar, March 2012
  • "Making contributions visible," 3rd Annual Women in Law conference, Calgary, AB, October 2009
  • "Partnerships: Policy and Research at the Crossroads: University-Industry Research Collaborations," 58th Canadian Chemical Engineering Conference, Ottawa, October 2008
  • "Patenting Therapeutic/Diagnostic Delivery Devices—Maximizing Marketing Potential," BioNorth Conference on Driving Global Innovation and Commercialization Through Partnerships, Ottawa, November 2007



  • "IP and trade deals: is CETA the last of its kind?", Intellectual Property Magazine, March 24, 2017
  • "CETA: are we there yet?"(co-author: Nancy Pei), Intellectual Property Magazine, December 7, 2016
  • "Sounding Out the Supreme Court of Canada on Utility", Best Lawyers, November 2016
  • "Coming to Canada: Information Protocol and Regulatory Issues" (co-author: Nancy Pei), BIOTECanada Insights, Spring 2016
  • "Will the TPP top CETA for protection of new drugs and biologics in Canada?" (co-author: Nancy Pei), Intellectual Property Magazine, February 2016
  • "Biopharmaceutical Companies Set to Benefit From International Trade Agreements" (co-author: Thuy Nguyen), Biotechnology Focus, December 2015/January 2016, p. 28
  • "Major changes to Canadian IP law" (co-author: Christian Bolduc), Intellectual Property Magazine, June 2014
  • "Enhanced IP rights in Canada" (co-author: Nancy P. Pei), Intellectual Property Magazine, December 2013
  • "Evolution of a Rare Medicines Policy in Canada" (co-author: Nancy P. Pei), insights Magazine, Fall 2013, pp. 16-19
  • "The Pharmaceutical/Biopharmaceutical Landscape—Traversing Canada's Patent and Regulatory Regimes" (co-author: Nancy P. Pei), Biotechnology Law Report, August 2013, Vol. 32, Issue 4, pp. 252-258
  • "A Bird's Eye View Of The Canadian Patent Landscape." (co-author: Sheldon Hamilton), Corporate Counsel IP Canada Report, August 2013
  • "Maximising potential – exploiting patent protection for biologics," Intellectual Property Magazine, July/August 2013
  • "Patentable subject matter" (co-authors: Steven B. Garland and Kevin K. Graham), Canadian Patent Law Benchbook 2012
  • "Evergreen IP," Intellectual Property Magazine, November 2012
  • "More effective protection for pharmaceuticals" (co-author: Steven B. Garland), Intellectual Property Magazine, July/August 2012
  • "Marketing Innovative Drugs in Canada," Corporate Livewire's Expert Guide: Intellectual Property, December 2011, pp. 72-74
  • "The utility of it all," Intellectual Property Magazine, November 2011
  • "Double Trouble: Canadian Courts Continue to Clarify the Law on Double Patenting," Intellectual Property Magazine, May 2010
  • "Canada Paves the Way for Subsequent Entry Biologics (SEBs)" (co-author: David E. Schwartz), Pharmaceutical Law Insight, May 2009
  • "A New Line in the Sand: Supreme Court of Canada considers 'Obvious to Try' and clarifies novelty and selection inventions," (co-author: Steven B. Garland), Patent World, April 2009
  • "What Brands Need to Know: Top 10 Tips for Successfully Protecting Exclusivity in the New Regulatory Framework" (co-authors: Gunars A. Gaikis and L. Catherine Eckenswiller), paper presented at the Canadian Institute seminar Pharmaceutical & Biotech Regulatory Compliance, March 2007
  • "Biotechnology: Recent Developments of Importance" (co-author: David E. Schwartz), The 2007 LEXPERT/ALM Guide to the Leading 500 Lawyers in Canada, January 2007, pp. 164-167
  • "Patenting life forms" (co-author: Elizabeth A. Hayes), Canadian Chemical News/L’Actualité chimique canadienne, October 2006, Vol. 58, No. 9, pp. 18-19
  • "Unique IP Issues in Canada's Pharmaceutical and Biotechnology Industry" (co-authors: Gunars A. Gaikis and David E. Schwartz), The 2006 LEXPERT Guide to the Top 100 Industry Specialists in Canada, October 2006, pp. 125-129
  • "Chemical and Biomedical Patenting in Canada: From Procurement to Enforcement," presented by John Morrissey at the Royal Chemical Society symposium Creating Business Through World Patent Enforcement, March 2006
  • "New Drug Discovery — Beyond the Bench-Top," Canadian Chemical News, April 2006
  • "Biopharma Innovators Stand to Benefit from Proposed Data Protection Regulations" (co-authors: May M. Lee and Joy D. Morrow), Bio-Science Law Review, Vol. 7, Issue 2, [2004/2005] 2 BLSR 97
  • "Innovation to Commercialization — The Role Patents Play," Canadian Chemical News, June 2005
  • "Net Benefits? Internet Pharmacies in Canada," Canadian Chemical News, May 2005
  • "Balancing Act," Canadian Chemical News, October 2004
  • "Regulating Beauty," Canadian Chemical News, July/August 2004
  • "The Patented Medicines (Notice of Compliance) Regulations" (co-author: Peter R. Wilcox), 16 Canadian Intellectual Property Reports 429, 2000
web design toronto Rebel Trail